RE: Covid treatment29 Jun 2020 21:31
https://www.proactiveinvestors.com/companies/news/922923/tiziana-life-sciences--aggressively-advancing--covid-19-treatment-and-breakthrough-delivery-method-922923.html
Timely step forward
STC Biologics’ CEO, Dr Magdalena Leszczyniecka, described the move to scaled-up, standardised manufacturing as a “timely step forward toward expediting development of potentially an innovative treatment for COVID-19 patients”.
The latest update from Tiziana heralded another in a series of potentially value-generative initiatives the life sciences company has underway.
Earlier this month it received a US patent for a breakthrough oral formulation of a monoclonal antibody that has been hailed as offering a “transformational avenue for immunotherapies”.
The patent protects the “lyophilised and stabilised free-flowing powder” of Foralumab contained in enteric-coated capsules for oral treatment of disease.
Foralumab is emerging as the jewel in the crown for Tiziana, which has clinical and pre-clinical assets spanning cancers, autoimmune and inflammatory diseases.
Best-in-class diagnostic
It also has a potentially best-in-class cancer diagnostic platform that it is spinning out into a separate company.
Eminent Wall Street analyst Raghuram Selvaraju, of H.C. Wainwright, recently flagged the huge potential value of the business, when he set a price target for the shares US$25, or £5 here in the UK. To put that in perspective, the US-listed American depository shares closed on Friday at US$5.93, while the UK stock ended £1.